Lack of protection against ebola virus from chloroquine in mice and hamsters

Emerging Infectious Diseases

Volumn 21, Issue 6, 2015, Pages 1065-1067

  Falzarano, Darryl ^a   Safronetz, David ^a   Prescott, Joseph ^a   Marzi, Andrea ^a   Feldmann, Friederike ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHLOROQUINE; DOXYCYCLINE; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EC50; HAMSTER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SURVIVAL; VIRUS LOAD; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; VETERINARY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHLOROQUINE; CRICETINAE; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MICE; VIRAL LOAD; VIRUS REPLICATION;

EID: 84929431373     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2106.150176     Document Type: Article

References (15)

1. De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015;93:1-10. http://dx.doi.org/10.1016/j.bcp.2014.11.008
2. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20:131-5. http://dx.doi.org/10.1016/S1386-6532(00)00139-6
3. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264-8. http://dx.doi.org/10.1016/j.bbrc.2004.08.085
4. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53:3416-21. http://dx.doi.org/10.1128/AAC.01509-08
5. Farias KJ, Machado PR, de Almeida Junior RF, de Aquino AA, da Fonseca BA. Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol. 2014;58:318-26. http://dx.doi.org/10.1111/1348-0421.12154
6. Delogu I, de Lamballerie X. Chikungunya disease and chloroquine treatment. J Med Virol. 2011;83:1058-9. http://dx.doi.org/10.1002/jmv.22019
7. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. [Erratum in: Lancet Infect Dis. 2011;11:655.] Lancet Infect Dis. 2011;11:677-83. http://dx.doi.org/ 10.1016/S1473-3099(11)70065-2
8. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS ONE. 2013;8:e60579. http://dx.doi.org/10.1371/journal.pone.0060579
9. Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother. 2015;49:196-206. http://dx.doi.org/10.1177/1060028014561227
10. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011;204(Suppl 3):S1066-74. http://dx.doi.org/ 10.1093/infdis/jir348
11. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1998;178:651-61. http://dx.doi.org/10.1086/515386
12. Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, et al. A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. J Infect Dis. 2013;207:306-18. http://dx.doi.org/10.1093/infdis/jis626
13. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271-93.
14. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ. 1978;56:247-70.
15. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis. 2010;4:e785. http://dx.doi.org/10.1371/journal.pntd.0000785